Short-acting ß2-agonists. Their influence on bronchial asthma course and mortality

1. Белоусов Ю.Б., Омельяновский В.В. Клиническая фармакология болезней органовдыхания. М.: Универсум Паблишинг; 1996.

2. National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 2: Guidelines for the diagnosis and management of asthma. National Institutes of Health publ. no 97—4051. Bethesda, MD; 1997.

3. p2-agonists. From pharmacological properties to everyday clinical practice: International workshop report. — London; 2000.

4. Barnes P.J. Effects of p2-agonists and steroids on P2-adrenoceptors. Eur. Respir. Rev. 1998; 8: 210—215.

5. Beasley R ., Pearce N., Crane J., Burgess C. Beta agonists: What is the evidence that their use increases the risk of asthma morbidity and mortality? J. Allergy Clin. Immunol. 1999; 104 (2): 197—202.

6. Benson R.L., Perlman F. Clinical effects of epinephrine by inhalation. J. Allergy 1948; 19: 129—140.

7. Bremner P., Siebers R., Crane J. et al. Partial vs full p-receptor agonism. — A clinical study of inhaled albuterol and fenoterol. Chest 1996; 109: 957—963.

8. British Thoracic Society. Guidelines for the management of asthma in adults. Br. Med. J. 1990; 301: 797—800.

9. Brittain R.T., Dean CM ., Jack D. Sympathomimetic bronchodilating drugs. In: Widdicombe J., ed. Respiratory pharmacology. Oxford, N.Y.: Oxford Pergamon Press; 1991. 613—652.

10. Burgess C.D., Windom II.H., Pearce N. et at. Lack of evidence for P2 receptor selectivity: a study of metaproterenol, fenoterol, isoproterenol and epinephrine in patients with asthma. Am. Rev. Respir. Dis. 1991; 143: 444—446.

11. Chapman K.R., Kesteen S., Szalai J.P. Regular vs as-needed inhaled salbutamol in asthma control. Lancet 1994; 343: 1379—1382.

12. O'Connor B.J., Aikman S.L., Barnes P.J. Tolerance to the nonbronchodilator effects of inhaled p-agonists in asthma. N. Engl. J. Med. 1992; 327: 1204—1208.

13. O’Donnell S.R. An examination of some beta-adrenoceptor stimulants for selectivity using the isolated trachea and atria of the guinea-pig. Eur. J . Pharmacol. 1972; 19: 371—379.

14. Drazen J.M., Israel E., Boushey H.A. et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N. Engl. J. Med. 1996; 335: 841—847.

15. McFadden E.R. Jr. Perspectives in p-agonist therapy: vox clamantis in deserto vel lux in tenebris? J. Allergy Clin. Immunol. 1995; 95: 641—651.

16. Haahtela T., Jarvinen M., Kava T. et al. Comparison of a p2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N. Engl. J. Med. 1991; 325: 388—392.

17. Inhaled P2-adrenergic agonists in asthma. Position statement from the American Academy of Allergy and Immunology. J. Allergy Clin. Immunol. 1993; 91: 1234—1237.

18. Jackson R.T., Beaglehole R., Rea H.H., Suther land D.C. Mortality from asthma: a new epidemic in New Zealand. Br. Med. J. 1982; 285: 771—774.

19. Kerrebijn K.F., van E s sen-Zandvliet E.E.M., Neijens H.J. Effect of long-term treatment with inhaled corticosteroids and P-agonists on the bronchial responsiveness in children with asthma. J. Allergy Clin. Immunol. 1987; 79: 653—659.

20. Kraan J., Koeter G.H., vd Mark T.W.et al. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. Ibid. 1985; 76: 628—636.

21. Lai C.K.W., Twentyman O.P., Holgate S.T. The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in non-specific bronchial responsiveness. Am. Rev. Respir. Dis. 1989; 140: 917—923.

22. Maconochie J.G., Minton N.A., Chilton J.E., Keene O.N. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol? Br. J. Clin. Pharmacol. 1994; 37: 199—204.

23. Malta E., Raper C. Non-catechol phenylethanolamines: agonistic actions on beta-adrenoceptors in isolated tissues from the guineapig. Clin. Exp. Pharmacol. Physiol. 1974; 1: 259—268.

24. Newnham D.M., Grove A., McDevitt D.G., Lipworth B.J. Subsensitivity of brcnchodilator and systemic P2-adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995; 50: 497—504.

25. Pearce N., Grainger J., A tkinson M. et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977—1981. Ibid. 1990; 45: 170—175.

26. Raper C., Malta E. Salbutamol: agonistic and antagonistic activity at p-adrenoceptor sites. J. Pharm. Pharmacol. 1973; 25: 661—663.

27. Sears M.R., Taylor D.R., Print C.G. et al. Regular inhaled p-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391—1396.

28. Sears M.R., Taylor D.R. The p2-agonist controversy: observations, explanations and relationship to asthma epidemiology. Drug Safety 1994;11:259-283.

29. Stolley P.D. Why the United States was spared an epidemic of deaths due to asthma. Am. Rev. Respir. Dis. 1972; 105: 883—890.

30. Taylor D.R., Town G.I., Herbison G.P. et. al. Asthma control during long term treatment with regular inhaled salbutamol and salmeterol. Thorax 1998; 53: 744—752.

31. Windom H.H., Burgess C.D., Crane J. et al. The self-administration of inhaled p-agonist drugs during severe asthma. N.Z. Med. J. 1990; 103: 205-207.